+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis



β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis



Plos One 7(7): E37659



The risk stratification of patients for heart failure (HF) remains a challenge, as well as the anticipation of the response to β-blocker therapy. Since the pivotal role of β1 adrenergic receptor (β1-AR) in HF, many publications have studied the associations between the β1-AR polymorphisms (Ser49Gly and Arg389Gly) and HF, with inconsistent results. Thus, we performed a meta-analysis of studies to evaluate the impact of β1-AR polymorphisms on susceptibility to HF, the response to β-blocker therapy and the prognosis of HF. Electronic databases were systematically searched before August 2011. We extracted data sets and performed meta-analysis with standardized methods. A total of 27 studies met our inclusion criteria. It was found that in East Asians, the Gly389 allele and Gly389 homozygotes significantly increased the HF risk, while the Gly389 allele and Gly389 homozygotes trended to decrease the risk of HF in whites. With the similar reduction of heart rate, overall, the Arg389 homozygotes showed a better response to β-blocker therapy. Furthermore, the Arg389 homozygotes were significantly associated with better LVEF improvement in East Asians and a mixed population. And in white people, the Arg389 homozygotes made a greater LVESd/v improvement and trended to be associated with better LVEDd/v improvement. However, the prognosis of Arg389 homozygotes HF patients was similar to those with Gly389 carriers. The Ser49Gly polymorphism did not impact the risk or prognosis of HF. Based on our meta-analysis, the Gly389 allele and Gly389 homozygotes were risk factors in East Asians while trending to protect whites against HF. Furthermore, Arg389 homozygote is significantly associated with a favorable response to β-blocker treatment in HF patients. However, neither of the two polymorphisms is an independent predictor of the prognosis of HF.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056998785

Download citation: RISBibTeXText

PMID: 22815685

DOI: 10.1371/journal.pone.0037659


Related references

Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. American Journal of Cardiology 102(6): 726-732, 2008

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity. Molecular Medicine Reports 7(1): 259-265, 2014

Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenetics and Genomics 17(4): 277-282, 2007

Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. European Journal of Heart Failure 10(1): 3-13, 2007

No racial differences in response to beta-blocker therapy for heart failure A meta-analysis. Circulation 104(17 Suppl.): II 681, October 23, 2001

A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. Journal of Cardiac Failure 15(3): 224-232, 2009

??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy. Pharmacogenetics and Genomics 15(4): 227-234, 2005

Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenetics and Genomics 15(4): 227-234, 2005

Consideration of beta-1 adrenergic receptor polymorphisms along with traditional risk factors as predictors of prognosis in patients with heart failure. Clinical Pharmacology & Therapeutics 75(2): P55, 2004

Polymorphisms of the beta-2 adrenergic receptors may influence the effects of beta-blocker therapy in the patients with chronic heart failure. European Heart Journal 24(Abstract Suppl.): 711, August-September, 2003

Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. Journal of Cardiac Failure 9(6): 464-468, 2004

Meta-analysis of beta-blocker therapy in heart failure. European Heart Journal 17(ABSTR Suppl. ): 79, 1996

Association of Gln27Glu and Arg16Gly polymorphisms in Beta2-adrenergic receptor gene with obesity susceptibility: a meta-analysis. Plos One 9(6): E100489, 2015

Association study of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene with susceptibility and prognosis of heart failure. Gene 510(1): 7-13, 2012

Beta-adrenergic receptor polymorphisms and antihypertensive response to beta-blocker therapy. Clinical Pharmacology & Therapeutics 71(2): P2, 2002